Analysts recently released new ratings on some health care companies.
Raymond James initiated coverage of PRA Health Sciences Inc. (PRAH, Financial) with an outperform rating. The analytics firm set a price target of $89 per share, which represents a 18.4% upside from the current market value of the stock.
PRA Health, a U.S. contract research company that provides outsourced clinical development services, has a market cap of $4.71 billion and an enterprise value of $5.43 billion, for an EV/EBITDA ratio of 19.48.
The stock is currently trading around $75.16 per share on the Nasdaq with a price-earnings (P/E) ratio of 48.45 and a price-book (P/B) ratio of 5.58. The forward P/E ratio is 19.62. The analysts’ EPS estimate is $3.19 for 2017. The average target price per share is $88.11. The recommendation rating, which ranges between 1.0 (Strong Buy) and 5.0 (Sell), is 1.5.
Morgan Stanley upgraded shares of Molina Healthcare Inc. (MOH, Financial) to overweight from the previous rating of underweight. The firm set a target price of $68 per share, which represents a 4.6% increase from the previous target price and a 19.8% upside from the current market value of Molina Healthcare.
The health care company provides low-income families and individuals with Medicaid-related solutions and government agencies with administration assistance services for their Medicaid program’s management.
Molina Healthcare has a market cap of $3.24 billion and an EV/EBITDA ratio of -1.54.
The stock is currently trading around $56.78 with a P/E ratio of 30.51 and a P/B ratio of 2.14. The forward P/E ratio is 19.81. The analysts’ EPS estimate is -$2.96 on average for full fiscal 2017. The average target price per share is $62.36. The recommendation rating is 3 out of 5.
Citigroup initiated coverage of Abbott Laboratories (ABT, Financial). The firm released an initial rating of neutral and set a target price of $53 per share. This represents a 6.4% upside to the current share price of the health care company.
Abbott Laboratories has a market cap of $86.54 billion. The stock is trading around $49.81 per share with a P/E ratio of 70.15 and a P/B ratio of 2.74. The forward P/E ratio is 20.16. The analysts’ EPS estimate is $2.49 for 2017, up 13.2% from 2016's EPS. The average target price per share is $55.06. The recommendation rating is 1.9.
The company distributes an annual dividend of $1.06 through quarterly payments of 26.5 cents, for a dividend yield of 2.16%.
With a neutral rating, the U.S. bank also initiated coverage of Baxter International Inc. (BAX, Financial). Citigroup set a target price of $63 per share, which represents a 2.7% upside from the current market value.
The renal and hospital products provider has a market cap of $33.43 billion. The stock is trading around $61.36 with a P/E ratio of 36.74 and a P/B ratio of 3.64. The forward P/E ratio is 25.64. The analysts’ EPS estimate is $2.39 for 2017, up 22% from 2016's EPS. The average target price per share is $67.25. The recommendation rating is 2.6.
The company distributes an annual dividend of 64 cents through quarterly payments of 16 cents, for a dividend yield of 1.06%.
Disclosure: I have no positions in any stocks mentioned in this article.
